Ani pharmaceuticals reports inducement grants under nasdaq listing rule 5635(c)(4)

Baudette, minn.--(business wire)--ani pharmaceuticals, inc. (“ani“ or the “company“) (nasdaq: anip) today announced that ani's board of directors granted non-qualified inducement stock options to purchase an aggregate of 27,006 shares of ani's common stock to ori gutwerg, ani's senior vice president, generics, and an aggregate of 33,758 shares to christopher mutz, ani's chief commercial officer & head of rare disease, effective february 15, 2021. the stock options were granted as inducement
ANIP Ratings Summary
ANIP Quant Ranking